Recombinant Human TNFSF14/LIGHT Protein (His Tag) | PKSH031639

Recombinant Human TNFSF14/LIGHT Protein (His Tag) | PKSH031639 | Gentaur US, UK & Europe Disrtribition

Synonyms: CD258;HVEML;LIGHT;LTg;TR2;Tumor necrosis factor ligand superfamily member 14; Herpes virus entry mediator ligand; TNFSF14; HVEM-L; LIGHT

Active Protein: N/A

Activity: A DNA sequence encoding the human TNFSF14 (NP_003798.2) extracellular domain (Asp 74-Val 240) was fused with a polyhistidine-tag at the N-terminus.

Protein Construction: A DNA sequence encoding the human TNFSF14 (NP_003798.2) extracellular domain (Asp 74-Val 240) was fused with a polyhistidine-tag at the N-terminus.

Fusion Tag: N-His

Species: Human

Expressed Host: HEK293 Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 85 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per µg as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 20.4 kDa

Formulation: Lyophilized from sterile PBS, pH 7.4

Reconstitution: Please refer to the printed manual for detailed information.

Background: LIGHT, also known as TNFSF14 or CD258, is a newly identified member of the TNF superfamily (TNFSF14) that is expressed by activated T lymphocytes, monocytes, granulocytes, spleen cells, and immature dendritic cells. TNFSF14 / LIGHT / CD258 is a type II transmembrane protein that is known to bind 2 membrane-bound TNFSF signaling receptors: HVEM, which is predominantly expressed by T cells, and lymphotoxin β receptor (LTβR), which is expressed by stromal cells and nonlymphoid hematopoietic cells. TNFSF14 / LIGHT / CD258 also binds to a soluble nonsignaling receptor, decoy receptor 3 (DcR3), which can modulate the function of LIGHT in vivo. TNFSF14 / LIGHT / CD258 can also costimulate T cell responses via HVEM, which is constitutively expressed in most lymphocyte subpopulations, including CD4+ and CD8+ T cells. In addition, TNFSF14 / LIGHT / CD258 has been shown to suppress tumor formation in vivo and to induce tumor cell apoptosis via the up-regulation of intercellular adhesion molecule 1 and an increased lymphocyte adhesion to cancer cells. Thus, TNFSF14 / LIGHT / CD258 is being actively investigated as a possible basis for cancer treatment.Immune CheckpointImmune Checkpoint ProteinsImmune Checkpoint Targets   Co-stimulatory Immune Checkpoint Targets Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Research Area: immunology